BioNTech (BNTX) officer details options, PSUs, RSUs and shares in Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
BioNTech SE officer Ryan James Timothy Patrick filed an initial ownership report showing existing equity awards and share holdings. He holds options over 25,459 and 8,838 ordinary shares with exercise prices of EUR 75.91 and EUR 93.35 that vest annually over four years and become exercisable four years after grant, subject to performance and other conditions. He also holds 11,047 performance share units, plus restricted stock units over 740 and 750 ordinary shares that vest in equal annual installments over four years with a four-year waiting period. In addition, he directly owns 4,795 ordinary shares, including 3,990 held jointly with his spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Ryan James Timothy Patrick
Role
See remarks.
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Performance Share Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 25,459 shares (Direct);
Performance Share Unit — 11,047 shares (Direct);
Restricted Stock Unit — 740 shares (Direct);
Ordinary Shares — 4,795 shares (Direct)
Footnotes (1)
- Includes 3,990 shares held jointly with the Reporting Person's spouse. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board. The exercise price of this option is EUR 75.91. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price. The exercise price of this option is EUR 93.35. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date. The restricted stock units ("RSUs") vest in equal annual installments over four years commencing on the grant date and are subject to a four-year waiting period. The RSUs may be settled in ordinary shares, ADSs, and/or cash at the election of the plan administrator. Each RSU represents a contingent right to receive one ordinary share, one ADS, and/or the cash equivalent thereof at the election of the plan administrator.
FAQ
What does the BioNTech (BNTX) Form 3 filing by Ryan James Timothy Patrick show?
The Form 3 shows Ryan James Timothy Patrick’s existing BioNTech equity interests, including options, performance share units, restricted stock units, and ordinary shares. It is an initial ownership report, not a record of new purchases or sales of BioNTech stock.
How many BioNTech options does Ryan James Timothy Patrick report on his Form 3?
He reports options linked to 25,459 and 8,838 BioNTech ordinary shares. These options vest annually in equal installments over four years and become exercisable four years after grant, subject to performance-based and other conditions described in the footnotes.
What restricted stock units does Ryan James Timothy Patrick hold in BioNTech?
He holds restricted stock units over 740 and 750 BioNTech ordinary shares. These RSUs vest in equal annual installments over four years and are subject to a four-year waiting period, with settlement potentially in shares, ADSs, cash, or a combination.